

# Anxiolytic/Hypnotic Treatment Selector

Charts reviewed December 2023. Full information available at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV oral	FTR	LEN	MVC	BIC/F/TAF	CAB oral	CAB/RPV	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC/TAF	FTC/TDF
<b>Anxiolytics</b>																						
Alprazolam	↑	↑ <sup>a</sup>	↑	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Bromazepam	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Bupirone	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Clorazepate	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Diazepam	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Lorazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Oxazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Hypnotics</b>																						
Chlordiazepoxide	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Estazolam	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Flunitrazepam	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Flurazepam	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Lormetazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Midazolam (oral)	↑	↑	↑	↑	↑	↓18%	↓ <sup>b</sup>	↓	↓	↔	↔	↑259%	↑18%	↑15%	↑10%	↔	↔	↔	↑	↑	↓8%	↔
Temazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Triazolam	↑	↑	↑	↑	↑	↔	↓ <sup>b</sup>	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Valerian	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zaleplon	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Zolpidem	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔
Zopiclone	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔

**Interactions with CAB/RPV long acting injections**

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

**Interactions with Lenacapavir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**

None

**Interactions with Abacavir (ABC), Lamivudine (3TC), Tenofovir-DF (TDF) or Zidovudine (ZDV)**

ABC: No clinically relevant interactions expected.  
 3TC: No clinically relevant interactions expected.  
 TDF: No clinically relevant interactions expected.  
 ZDV: No clinically relevant interactions expected.

**Colour Legend**

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

**Text Legend**

- ↑ Potential increased exposure of the anxiolytic/hypnotic
- ↓ Potential decreased exposure of the anxiolytic/hypnotic
- ↔ No significant effect

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

**Notes**

- a** Initial inhibitory effect followed by inductive effect in presence of ritonavir. Start alprazolam at a lower dose and increase if needed.
- b** The efavirenz European SPC (but no longer the US Prescribing Information) contraindicates coadministration citing competition for CYP3A4 by efavirenz as a potential mechanism for inhibition of midazolam or triazolam metabolism which may result in potential serious and/or life-threatening adverse events.